Water-Soluble C60 Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice
Received 1 May 2019
Accepted for publication 16 December 2019
Published 31 March 2020 Volume 2020:15 Pages 2269—2276
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Linlin Sun
Run Dong,1,2,* Min Liu,3,* Xiao-Xi Huang,4 Zheng Liu,4 Ding-Yuan Jiang,5 Hui-Juan Xiao,1 Jing Geng,5 Yan-Hong Ren,5 Hua-Ping Dai5
1Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Department of Respiratory Medicine, Capital Medical University, Beijing, People’s Republic of China; 2Department of Respiratory Medicine, Zhengzhou Central Hospital, Zhengzhou, People’s Republic of China; 3Department of Radiology, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 4Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Department of Medical Research, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, People’s Republic of China; 5Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases; Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hua-Ping Dai
Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing 100029, People’s Republic of China
Email [email protected]
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial pneumonia. And, oxidation/antioxidant imbalance plays an important role in the progress of IPF. Fullerene is considered to be a novel “structural” antioxidant. This study aimed to explore if water-soluble C60 (C60(OH)22) can exhibit antifibrotic activity in its antioxidant role.
Methods: Healthy C57BL/6J mice were randomly grouped and induced pulmonary fibrosis by intratracheal injection of bleomycin.
Results: The survival rate of mice was observed and found that 10mg/kg was the optimal dose of water-soluble C60 for pulmonary fibrosis. We observed that water-soluble C60 can alleviate the severity of pulmonary fibrosis by observing the chest computed tomography, pulmonary pathology, and content of collagen, alpha smooth muscle actin and fibronectin in lung. Compared with bleomycin group, ROS, the content of TNF-α in BALF, and the number of fibroblasts was significantly decreased and the number of type Ⅱ alveolar epithelial cells was increased after treatment with C60.
Conclusion: Therefore, thanks to its powerful antioxidant action, water-soluble C60 can reduce the severity of pulmonary fibrosis induced by bleomycin in mice.
Keywords: pulmonary fibrosis, bleomycin, water-soluble C60, mice
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia with unknown causes. The median survival time of IPF patients is 2–3 years from diagnosis with a 5-year mortality of 30–50%. There is no effect therapy except lung transplantation.1 Furthermore, potent new agents are urgently needed.
The pathogenic mechanisms of IPF remain unclear. It is currently believed that IPF originates from the abnormal repair of alveolar epithelium after repeated minor damage, which leads to scarring and lung tissue destruction.2 For the past few years, it is discovered that oxidation/antioxidant imbalance plays an important role in the progress of IPF.3 Reduced oxidative stress can reduce the degree of pulmonary fibrosis.4
Oxidative stress is an imbalance between oxidants such as reactive oxygen species (ROS) and antioxidants, which may affect lipids, DNA, carbohydrates and proteins. ROS is free radical generated physiologically during oxidative phosphorylation, including superoxide anion, hydroxyl and hydrogen peroxide. It has various physiological roles such as causing cell dysfunction and death. Research has shown that oxidants and myeloperoxidase of cells in bronchoalveolar lavage fluid (BALF) increased to a higher concentration in IPF patients,5 and the epithelial injury in IPF was related to the increasing activity of peroxidase. Daniil et al had determined oxidative burden in serum based on analysis of hydroperoxides6 and found that systemic oxidative stress level in IPF was significantly higher than that in control, and it was negatively correlated with dyspnea severity and lung function marked by forced vital capacity and diffuse lung capacity for carbon monoxide. In summary, the oxidation/antioxidant imbalance is related to the progression of idiopathic pulmonary fibrosis.
Fullerene was considered to be a novel “structural” antioxidant and characterized as a “radical sponge” by Krusic et al7. Water-soluble fullerene C60 is nontoxic at low physiological concentrations,8,9 which is able to penetrate through the membrane of cells10,11 and have strong antioxidant properties.8 Moreover, it has been found that fullerene C60 possesses anticancer activity.12,13
In this study, we aimed to explore if water-soluble C60 (C60(OH)22) can exhibit antifibrotic activity in a murine model of bleomycin (BLM) induced pulmonary fibrosis by its antioxidant role.
Materials and Methods
Specific pathogen-free (SPF) C57BL/6J mice were purchased from the Animal Center of Peking University (Beijing, China), and fed under SPF conditions in the basic Medical Research Center of Beijing Chaoyang Hospital affiliated to Capital Medical University. Male mice aged 7–8 weeks and weighing 22–25g were used for the preparation of bleomycin-induced pulmonary fibrosis in mice. The care and use of laboratory animals in this study was according to the National Institutes of Health guide strictly. This study was approved by the Animal Care and Utilization Committee of Capital Medical University (AEEI-2014-034).
Preparation of Water-Soluble C60 and Pirfenidone
C60(OH)22 with purity of more than 99.9% was obtained from Suzhou Dade Carbon Nanotechnology Co., Ltd. C60(OH)22 was dissolved in sterilized and apyrogenic physiological saline (0.9%). Pirfenidone was purchased from Beijing Continent Pharmaceutical Co. Ltd.
The animals were randomly divided into 10 groups in the following way.
For exploring the preventive effects are there 1) NS (normal saline) group–mice received saline only; 2) BLM group–mice received BLM, treatment–saline (per day); 3) 1 mg/kg group–mice received BLM, treatment–C60(OH)22 1 mg/kg/day; 4) 10 mg/kg group–mice received BLM, treatment–C60(OH)22 10 mg/kg/day; 5) 100 mg/kg group–mice received BLM, treatment–C60(OH)22, 100 mg/kg/day; 6) 500 mg/kg group–mice received BLM, treatment–C60(OH)22, 500 mg/kg/day.
For exploring the therapeutic effects are there 1) NS group – mice received saline only; 2) BLM group–mice received BLM, treatment–saline (per day); 3) BLM + C60 group–mice received BLM, treatment–C60(OH)22 10 mg/kg/day; 4) BLM + pirfenidone group–mice received BLM, treatment–pirfenidone 300 mg/kg/day.
All mice (except NS group) were treated with a single intratracheal injection of 3.5 (preventive) or 2.0 (therapeutic) mg/kg body weight BLM hydrochloride diluted by saline.14 C60(OH)22 and pirfenidone were administered intraperitoneal injection beginning from the first day (preventive) and 14th day (therapeutic) until mice were sacrificed after 21 days (preventive) and 28 days (therapeutic) after intratracheal injection of BLM (Figure 1). Moreover, blood, bronchoalveolar lavage fluid (BALF) and lung tissue were collected as previously described,15 the left lung was fixed by 10% formaldehyde solution, the right lung was frozen at −80°C for using.
Figure 1 Treatment and experimental regimen. Abbreviations: i.t., injection via the intratracheal route; i.p., intraperitoneal injection; i.g., intragastric administration; qd, once a day; bid, twice a day.
Lung Histological Assessment
The collection of mouse lungs for histology was performed as conventional treatment.16 Briefly, the lung was fixed (by 10% formaldehyde solution), dehydrated, paraffin-embedded, and cut into 4-μm sections. Lung sections were stained with H&E and Masson’s trichrome stain for assessment of pathological changes.17 Immunostaining was performed using antibodies against Collagen I (Abcam, Cambridge, USA), surfactant protein C (Abcam, Cambridge, USA) and alpha smooth muscle (α-SMA) antibody (Abcam, Cambridge, USA).
The content of hydroxyproline in the lung were measured using conventional methods.18 The content of hydroxyproline was calculated based upon the lung weight, and the data were expressed as micrograms of hydroxyproline in each gram of lung tissue.
Concentrations of TGF-β1 and TNF-α in lung tissue, BALF and plasma were determined using ELISA kits (Invitrogen, USA) according to the manufacturer’s instructions.
Protein Extraction and Western Blot Analysis
Frozen lung tissues were homogenized using RIPA buffer (Solarbio, Beijing, China) containing 1:100 phenylmethylsulfonyl fluoride (PMSF) and phosphatase inhibitors. The total protein concentration was resuspended in protein loading buffer containing 5% mercaptoethanol. The proteins were separated by 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Bio-Rad, Hercules, CA, USA) using a Mini-Protean electrophoresis module assembly (Bio-Rad) at 80 mV and transferred to nitrocellulose membranes (Millipore, Billerica, MA, USA) for 100 min using the Mini Trans-Blot electrophoresis transfer cell (Bio-Rad) at 300 mA. The membranes were treated with anti-rabbit or anti-mouse IgG (LI-COR, Lincoln, NE, USA). Positive bands were visualized, and the intensity of the bands was evaluated using a LI-COR Odyssey. The primary antibodies used were anti-fibronectin antibody (Abcam, Cambridge, USA), anti-α-SMA antibody (Abcam, Cambridge, USA) and anti-β actin antibody (Abcam, Cambridge, USA).
We performed survival analysis in each preventive group (n=9–10). Survival time of each mouse was recorded until 21st day after BLM or saline administration.
Measurement of ROS Concentration
The content of ROS was measured by using DCFH-DA as the manufacturer’s instructions, which was purchased from Nanjing Jiancheng Bioengineering Institute.
All data were expressed as the mean ± SD. All experiments were conducted with three independent replications. GraphPad Prism 6 (GraphPad, La Jolla, CA, USA) was used for statistical analyses using t-test or one-way analysis of variance; P < 0.05 was considered to indicate statistically significant differences in all comparisons.
The Optimal Dose of C60(OH)22 for Pulmonary Fibrosis Was 10 mg/kg/day
The mortality had a significant difference between preventive groups. All mice in NS group survived for 21 days. However, substantial mortality of mice was demonstrated in BLM group, and a significant change of median survival time existed between the group treated with C60(OH)22 10 mg/kg/day and the BLM group (Figure 2A). Up to the 21st day, 30% of mice survived in BLM group, 44.4% in C60(OH)22 1 mg/kg group and 100 mg/kg group, 66.7% in 10 mg/kg group, and no mice survived in 500 mg/kg group. These results indicated that C60(OH)22 could protect mice from death when mice were treated with the dose of 10 mg/kg/day and 1 mg/kg/day, but the mice treated with C60(OH)22 by the dose of 100 mg/kg/day had no difference with BLM group, what is more, C60(OH)22 with a dose of 500 mg/kg/day had injury but no advantage.
Body weight of mice in preventive groups (except NS group) had a significant decrease. However, compared to BLM group, the mice in 10 mg/kg group had a slight decrease, but the difference was not significant (Figure 2B).
C60(OH)22 Had a Therapeutic Effect in the Advanced Stages of BLM-Induced Pulmonary Fibrosis
Computed Tomography Images of Mice Lung
CT images of mice lung on the 28th day after BLM or saline administration are shown in Figure 2A. Lungs in the BLM groups demonstrated some consolidated shadows compared with the NS group (Figure 3A). However, compared with BLM group, the images of lungs in BLM+C60 group revealed decreased density and diffuse ground-glass opacities with or without areas of consolidation (Figure 3A), but quantitative evaluation was difficult.
H&E and MASSON
BLM-induced pulmonary injury and fibrosis in mice were monitored by histopathological analysis. It was shown that BLM instillation produced a significant increase of fibrosis in the lung by H&E-stained sections. BLM-induced fibrotic mice demonstrated increased pulmonary parenchymal distortion, showing thicker alveolar membrane, collapsed alveoli, and inflammatory cell infiltration (Figure 3A). Masson’s trichrome staining of collagen was used to demonstrate that BLM induced severe collagen deposition in mice. However, C60(OH)22 and pirfenidone administration markedly ameliorated lung injuries and evidently attenuated collagen deposition (Figure 3A).
Hydroxyproline was concentrated in BLM-induced inflammatory response, and there was a positive correlation between the level of hydroxyproline and collagen. As illustrated (Figure 3C), the hydroxyproline was significantly increased after BLM administration while reversed after C60(OH)22 and pirfenidone treatment.
Collagen Ι, α-SMA and Fibronectin
We subsequently investigated the ability of C60(OH)22 to modulate the expression of collagen Ι, α-SMA and fibronectin which were key markers of pulmonary fibrosis. The results showed that the lung tissues from BLM treated mice were markedly up-regulated the expression of collagen Ι, α-SMA and fibronectin (Figure 3A and B). Impressively, levels of α-SMA and fibronectin were obviously reduced after C60(OH)22 and pirfenidone treatment (Figure 3B). The expression of collagen Ι was monitored by immunohistochemical analysis. Lung sections of mice in NS group showed weak positive staining of collagen Ι, while intratracheal instillation of BLM resulted in markedly increased expression of collagen Ι in lung tissues. The administration C60 or pirfenidone largely decreased the expression of collagen Ι compared with BLM group (Figure 3A and D). These results directly reflected the attenuation effect of C60(OH)22 on BLM-induced pulmonary fibrosis in mice.
Mechanisms for the Therapeutic Effect of C60(OH)22 on BLM-Induced Pulmonary Fibrosis
The levels of ROS were determined in the lung tissue in order to investigate the effect of C60(OH)22 against the oxidative stress in BLM-induced lung fibrosis (Figure 4A). A significant rise in the level of ROS in lung tissue was observed in the BLM treated animals, while it was reversed after C60(OH)22 administration (P<0.05).
TGF-β1 and TNF-α
TGF-β1 and TNF-α play important roles in the pathogenesis and exacerbation of pulmonary fibrosis,19 and we assessed the effect of C60(OH)22 on their expression. As shown in Figure 4E and F., the expression of TGF-β1 and TNF-α in lung tissue, BALF and plasma were significantly increased in BLM group compared with NS group while it was decreased after C60(OH)22 administration, which suggested that C60(OH)22 could inhibit the expression of TGF-β1 and TNF-α.
AECⅡ and α-SMA
Type 2 alveolar epithelial cells (AECⅡ) were marked with surfactant protein C (SPC) by immunohistochemistry (Figure 4B and C). Compared with NS group, lung sections of BLM group were characterized by a significant decrease in the number of AECⅡ, while, the number rose again in mice receiving C60 group. α-SMA was monitored by immunohistochemical to reflect the amount of fibroblast. The sections in the NS group showed weak positive staining of α-SMA, while increasing expression was showed in BLM group (Figure 4B and D). These results directly reflected that C60(OH)22 could decrease the apoptosis of AECⅡand the amount of fibroblast by easing oxidative stress.
In this study, water-soluble C60 was found to serve as an antifibrotic agent for BLM-induced mouse pulmonary fibrosis, which has been used as a classic model for the evaluation of the antifibrotic effect.20 The results showed that BLM could induce pulmonary fibrosis and cause mice death, body weight loss and exacerbated lung histopathology abnormalities with collagen deposition. However, these adverse consequences caused by BLM were effectively attenuated by water-soluble C60. Our study had shown that water-soluble C60 possessed significant anti-inflammation and anti-oxidant effects on BLM-induced lung damage in mice. To the best of my knowledge, it is the first time to detect the role of C60, a novel “structural” antioxidant, in pulmonary fibrosis mice induced by bleomycin.
It has been reported by many studies that oxidative stress is closely related to the development of IPF.5,6,21 The excessive production of ROS plays a key role in oxidative stress, and ROS is also an important medium in the process of pulmonary fibrosis. It has been shown that ROS can make single-stranded DNA damage and fracture, resulting in AEC injury and necrosis. And the excessive production of ROS can induce AEC apoptosis by activating the death receptor pathway,22 mitochondrial death pathway23 and endoplasmic reticulum-associated death.24 Therefore, the activation of fibroblast and the deposition of collagen are promoted, and then, pulmonary fibrosis progresses. Our study showed that water-soluble C60 can significantly reduce the concentration of ROS in lung tissue. And we observed that water-soluble C60 could reduce the apoptosis and/or necrosis of AEC and decreased fibroblast activation. These results suggest that the development of IPF would be inhibited by water-soluble C60.
In addition, ROS could regulate signal transduction.25 ROS could increase the expression of TGF-β1, TNF-α, interleukin, platelet-derived growth factor Chaudhary et al.26 Among them, TGF-β1 plays a key role in pulmonary fibrosis which is called the “master switch” of organ fibrosis (including pulmonary fibrosis).27 To a certain extent, the degree of inflammation and fibrosis is depended on the quantity of TGF-β1.28,29 Apoptosis of AEC was mediated by TNF-α. TNF-α which is an important factor in the process of pulmonary fibrosis was up-regulated the expression of TGF-β1.30 The over-expression of these cytokines aggravated the damage and apoptosis of cells and advanced the development of pulmonary fibrosis. While ROS has been shown to activate these cytokines, and these cytokines also increase the production of ROS in human lung fibroblasts, so a vicious circle formed. In our study, we observed that the content of TGF-β1 and TNF-α significantly decreased in the lungs of mice after treated with C60(OH)22 compared with BLM group, suggesting water-soluble C60 could reduce the expression of TGF-β1 and TNF-α. Therefore, eventually, alleviate inflammation and inhibit fibrosis by reducing the content of ROS.
IPF is a chronic and fatal disease, and the management of IPF is highly debatable and no curative treatment has been developed except for pirfenidone and nintedanib. However, adverse events such as gastrointestinal symptoms, photosensitivity and fatigue might occur at pirfenidone administration.31,32 And nintedanib slowed disease progression with side-effect profiles such as hepatic enzymes increased, Mazzei et al33 However, Gharbi et al have shown that fullerene C60 is a powerful antioxidant with no acute or subacute toxicity.8,9 Baati et al have found that the lifespan of rats would be prolonged by repeated oral administration of fullerene C60.34 Therefore fullerene C60 is likely to be a new management of IPF.
It was demonstrated that water-soluble C60, a novel “structural” antioxidant, could reduce the severity of pulmonary fibrosis induced by BLM in mice. Therefore, water-soluble C60 probably has a great potential for IPF therapeutic applications.
This work was supported by grants from National Natural Science Foundation of China [Nos. 81430001, 81470258 and 81871328] and Beijing Natural Science Foundation [No. 7182149].
The authors declare no conflicts of interest in this work.
1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi:10.1164/rccm.2009-040GL
2. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–151. doi:10.7326/0003-4819-134-2-200101160-00015
3. Wadsworth RM. Oxidative stress and the endothelium. Exp Physiol. 2008;93(1):155–157. doi:10.1113/expphysiol.2007.038687
4. Teixeira KC, Soares FS, Rocha LG, et al. Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Pulm Pharmacol Ther. 2008;21(2):309–316. doi:10.1016/j.pupt.2007.07.006
5. Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest. 1987;79(6):1665–1673. doi:10.1172/JCI113005
6. Daniil ZD, Papageorgiou E, Koutsokera A, et al. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2008;21(1):26–31. doi:10.1016/j.pupt.2006.10.005
7. Krusic PJ, Wasserman E, Keizer PN, et al. Radical reactions of c60. Science. 1991;254(5035):1183–1185. doi:10.1126/science.254.5035.1183
8. Gharbi N, Pressac M, Hadchouel M, et al. fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005;5(12):2578–2585. doi:10.1021/nl051866b
9. Johnston HJ, Hutchison GR, Christensen FM, et al. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci. 2010;114(2):162–182. doi:10.1093/toxsci/kfp265
10. Qiao R, Roberts AP, Mount AS, et al. Translocation of C60 and its derivatives across a lipid bilayer. Nano Lett. 2007;7(3):614–619. doi:10.1021/nl062515f
11. Prylutska S, Bilyy R, Overchuk M, et al. Water-soluble pristine fullerenes C60 increase the specific conductivity and capacity of lipid model membrane and form the channels in cellular plasma membrane. J Biomed Nanotechnol. 2012;8(3):522–527. doi:10.1166/jbn.2012.1404
12. Shi J, Wang L, Gao J, et al. A fullerene-based multi-functional nanoplatform for cancer theranostic applications. Biomaterials. 2014;35(22):5771–5784. doi:10.1016/j.biomaterials.2014.03.071
13. Panchuk RR, Prylutska SV, Chumakl VV, et al. Application of C60 Fullerene-doxorubicin complex for tumor cell treatment in vitro and in vivo. J Biomed Nanotechnol. 2015;11(7):1139–1152. doi:10.1166/jbn.2015.2058
14. Li XX, Jiang DY, Huang XX, et al. Toll-like receptor 4 promotes fibrosis in bleomycin-induced lung injury in mice. Genet Mol Res. 2015;14(4):17391–17398. doi:10.4238/2015.December.21.8
15. Jiang D, Liang J, Hodge J, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest. 2004;114(2):291–299. doi:10.1172/JCI16861
16. Jiang DY, Huang XX, Jing G, et al. Pulmonary fibrosis in a mouse model of sarcoid granulomatosis induced by booster challenge with Propionibacterium acnes. Oncotarget. 2016;7(23):33703–33714. doi:10.18632/oncotarget.9397
17. Hübner RH, Gitter W, El MNE, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44(4):
18. Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181(3):254–263. doi:10.1164/rccm.200810-1615OC
19. Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L525–34. doi:10.1152/ajplung.00163.2007
20. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med. 2011;17(5):355–361. doi:10.1097/MCP.0b013e328349ac2b
21. Gao F, Koenitzer JR, Tobolewski JM, et al. Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. J Biol Chem. 2008;283(10):6058–6066. doi:10.1074/jbc.M709273200
22. Liu G, Beri R, Mueller A, Kamp DW. Molecular mechanisms of asbestos-induced lung epithelial cell apoptosis. Chem Biol Interact. 2010;188(2):309–318. doi:10.1016/j.cbi.2010.03.047
23. Fu YQ, Fang F, Lu ZY, et al. N-acetylcysteine protects alveolar epithelial cells from hydrogen peroxide-induced apoptosis through scavenging reactive oxygen species and suppressing c-Jun N-terminal kinase. Exp Lung Res. 2010;36(6):352–361. doi:10.3109/01902141003678582
24. Jorgensen E, Stinson A, Shan L, et al. Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. BMC Cancer. 2008;8(1):229. doi:10.1186/1471-2407-8-229
25. Rees MD, Kennett EC, Whitelock JM, et al. Oxidative damage to extracellular matrix and its role in human pathologies. Free Radic Biol Med. 2008;44(12):1973–2001. doi:10.1016/j.freeradbiomed.2008.03.016
26. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976–985. doi:10.1183/09031936.00152106
27. Sime PJ, O’Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 2001;99(3):308–319. doi:10.1006/clim.2001.5008
28. Cuzzocrea S, Genovese T, Failla M, et al. Protective effect of orally administered carnosine on bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1095–104. doi:10.1152/ajplung.00283.2006
29. Kang HR, Lee CG, Homer RJ, et al. Semaphorin 7A plays a critical role in TGF-β1–induced pulmonary fibrosis. J Exp Med. 2007;204(5):1083–1093. doi:10.1084/jem.20061273
30. Failla M, Genovese T, Mazzon E, et al. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res. 2006;7(1):137. doi:10.1186/1465-9921-7-137
31. Takeda Y, Tsujino K, Kijima T, et al. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence. 2014;8:361–370. doi:10.2147/PPA
32. Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(5):740–747. doi:10.1111/resp.12297
33. Mazzei ME, Richeldi L, Collard HR. Nintedanib in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2015;9(3):121–129. doi:10.1177/1753465815579365
34. Baati T, Bourasset F, Gharbi N, et al. The prolongation of the lifespan of rats by repeated oral administration of fullerene. Biomaterials. 2012;33(19):4936–4946. doi:10.1016/j.biomaterials.2012.03.036
© 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.